Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
glp-1 without prescription People Diabetes Make Up Growing Share of Users Quantity:Triple-Pack ($169) L-Isoleucine GLP-1 Receptor Agonist Market
GLP-1 Receptor Agonist Market Growth Analysis | CAGR Of 17.5%
The very short plasmatic half-life represents a major limitation for the possible use of GLP-1 in the clinical setting
L-Isoleucine
Quantity:Triple-Pack ($169)
Phase 2 Trial Design Participants: 338 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
US$ 27.07
US$ 24.37
US$ 28.33
US$ 26.19
US$ 21.88
US$ 23.11
